238 related articles for article (PubMed ID: 32162819)
1. Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study.
Brighi N; Panzuto F; Modica R; Gelsomino F; Albertelli M; Pusceddu S; Massironi S; Lamberti G; Rinzivillo M; Faggiano A; Spallanzani A; Ferone D; Prinzi N; Rossi RE; Annibale B; Colao AM; Campana D
Oncologist; 2020 Mar; 25(3):259-265. PubMed ID: 32162819
[TBL] [Abstract][Full Text] [Related]
2. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study.
Brighi N; Lamberti G; Maggio I; Manuzzi L; Ricci C; Casadei R; Santini D; Mosconi C; Lisotti A; Ambrosini V; Pantaleo MA; Campana D
Dig Liver Dis; 2019 May; 51(5):689-694. PubMed ID: 30314949
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
[TBL] [Abstract][Full Text] [Related]
4. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
[TBL] [Abstract][Full Text] [Related]
5. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs in pregnant patients with neuroendocrine tumor.
Meoni G; Giommoni E; Petreni P; Pillozzi S; Mazzoni F; Pellegrini E; Brugia M; Lunghi A; Muto A; Antonuzzo L
Anticancer Drugs; 2020 Nov; 31(10):1096-1098. PubMed ID: 32590392
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
10. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
11. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.
Lamberti G; Faggiano A; Brighi N; Tafuto S; Ibrahim T; Brizzi MP; Pusceddu S; Albertelli M; Massironi S; Panzuto F; Badalamenti G; Riccardi F; Butturini G; Gelsomino F; De Divitiis C; Modica R; Bongiovanni A; La Salvia A; Torchio M; Colao A; Ferone D; Campana D
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31545377
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center.
Jalbert JJ; Casciano R; Meng J; Brais LK; Pulgar SJ; Berthon A; Dinet J; Kulke MH
Oncologist; 2020 Apr; 25(4):e644-e650. PubMed ID: 31999024
[TBL] [Abstract][Full Text] [Related]
13. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Merola E; Panzuto F; Delle Fave G
Oncotarget; 2017 Jul; 8(28):46624-46634. PubMed ID: 28402955
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286
[TBL] [Abstract][Full Text] [Related]
16. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
[TBL] [Abstract][Full Text] [Related]
17. Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours.
Sorbye H; Meyer LS; Mordal KE; Myhre S; Thiis-Evensen E
Health Qual Life Outcomes; 2020 Jun; 18(1):188. PubMed ID: 32546236
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumors' patients treated with somatostatin analogue could complicate with emergency cholecystectomy.
Calomino N; Poto GE; Carbone L; Bagnacci G; Piccioni S; Andreucci E; Nenci L; Marano L; Verre L; Petrioli R; Roviello F; Marrelli D
Ann Ital Chir; 2023; 94():518-522. PubMed ID: 38051513
[TBL] [Abstract][Full Text] [Related]
20. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
Broder MS; Cai B; Chang E; Yan T; Benson AB
J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
